Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19.

DiNicolantonio, James J; Barroso, Jorge; McCarty, Mark

DiNicolantonio, James J; Barroso, Jorge; McCarty, Mark.

DiNicolantonio JJ; Department of Preventive Cardiology, Mid America Heart Insitute, Kansas, Missouri, USA jjdinicol@gmail.com.
Barroso J; Clinica Libre de Adicciones, Tijuana, Baja California, Mexico.
McCarty M; Catalytic Longevity Foundation, San Diego, California, USA.

Open Heart ; 7(2)2020 09.

Article in English | MEDLINE | ID: covidwho-748816

Subject(s)

Anti-Inflammatory Agents/administration & dosage; Betacoronavirus/drug effects; Coronavirus Infections/drug therapy; Ivermectin/administration & dosage; Pneumonia, Viral/drug therapy; Animals; Anti-Inflammatory Agents/adverse effects; Betacoronavirus/immunology; Betacoronavirus/pathogenicity; COVID-19; Coronavirus Infections/diagnosis; Coronavirus Infections/immunology; Coronavirus Infections/virology; Drugs, Essential; Host-Pathogen Interactions; Humans; Ivermectin/adverse effects; Pandemics; Pneumonia, Viral/diagnosis; Pneumonia, Viral/immunology; Pneumonia, Viral/virology; SARS-CoV-2; Treatment Outcome; COVID-19 Drug Treatment

Keywords

anti-oxidants; inflammation; oxidative stress

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Ivermectin / Coronavirus Infections / Betacoronavirus / Anti-Inflammatory Agents Type of study: Diagnostic study / Prognostic study Topics: Long Covid Limits: Animals / Humans Language: English Year: 2020 Document Type: Article Affiliation country: Openhrt-2020-001350

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google